The Management of Thrombotic Thrombocytopenic Purpura in 2005

 

 Buy Article Permissions and Reprints

ABSTRACT

Thrombotic thrombocytopenic purpura is an uncommon disease that often presents with a striking and acute clinical picture. Although first described more than 80 years ago, the therapy has changed little since the discovery that plasma, and then plasma exchange, could bring about a remarkable response, changing survival rates from 20% to more than 80%. However, although plasma exchange is now considered the standard of care, there is still considerable discussion concerning the appropriate schedules for therapy and the types of fluids that should be used. Because plasma exchange (PE) is not effective in all patients, and at least 30% of patients will have one or more relapses, several adjuvant therapies have also been used. Most recently, this has included the use of rituximab to achieve an immunomodulatory effect.

REFERENCES

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
  PubMedGoogle Scholar
• 2 Moschcowitz E. An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries.  Arch Intern Med. 1925;  36 89-93
  CrossrefPubMedGoogle Scholar
• 3 Rubinstein M A, Kagan B M, MacGillviray M H, Merliss R, Sacks H. Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions.  Ann Intern Med. 1959;  51 1409-1419
  CrossrefPubMedGoogle Scholar
• 4 Bukowski R M, King J W, Hewlett J S. Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.  Blood. 1977;  50 413-417
  CrossrefPubMedGoogle Scholar
• 5 Amorosi E I, Ultmann J E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.  Medicine (Baltimore). 1966;  45 139-159
  CrossrefPubMedGoogle Scholar
• 6 Rock G, Shumak K H, Buskard N A and the Members of the CASG et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.  N Engl J Med. 1991;  325 393-397
  CrossrefPubMedGoogle Scholar
• 7 Bell W R, Braine H G, Ness P M, Kickler T S. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.  N Engl J Med. 1991;  325 398-403
  CrossrefPubMedGoogle Scholar
• 8 Byrnes J J, Khurana M. Treatment of thrombotic thrombocytopenic purpuras with plasma.  N Engl J Med. 1977;  297 1386-1389
  CrossrefPubMedGoogle Scholar
• 9 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
  CrossrefPubMedGoogle Scholar
• 10 Rock G, Shumak K H, Sutton D M et al.. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpuras. Members of the Canadian Apheresis Group.  Br J Haematol. 1996;  94 383-386
  CrossrefPubMedGoogle Scholar
• 11 Rock G, Anderson D, Clark W et al.. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet?.  Br J Haematol. 2005;  129 79-86
  CrossrefPubMedGoogle Scholar
• 12 Zeigler Z R, Shadduck R K, Gryn J F et al.. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP).  J Clin Apheresis. 2001;  16 19-22
  PubMedGoogle Scholar
• 13 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
  CrossrefPubMedGoogle Scholar
• 14 Furlan M, Robles R, Galbusera M et al.. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
  CrossrefPubMedGoogle Scholar
• 15 Rock G, Yousef H, Neurath D, Lu M. Levels of ADAMTS-13 in fresh, stored and solvent detergent treated plasma. Paper presented at: the CSTM Meeting 2005 Banff, Canada;
  Google Scholar
• 16 Yarranton H, Lawrie A S, Purdy G, Mackie I J, Machin S J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.  Transfus Med. 2003;  14 39-44
  PubMedGoogle Scholar
• 17 Moake J L, Chintagumpala M, Turner N et al.. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of TTP.  Blood. 1994;  84 490-497
  PubMedGoogle Scholar
• 18 Tandon N N, Rock G, Jamieson G A. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura.  Br J Haematol. 1994;  88 816-825
  CrossrefPubMedGoogle Scholar
• 19 Morrison J, McMillan R. Elevated platelet-associated lgG in thrombotic thrombocytopenic purpura.  JAMA. 1977;  238 1944-1945
  CrossrefPubMedGoogle Scholar
• 20 Leung D Y, Moake J L, Havens P L, Kim M, Pober J S. Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome.  Lancet. 1988;  2 183-186
  PubMedGoogle Scholar
• 21 Gilcher R O, Strauss R G, Clavarella D et al.. Management of renal disorders.  J Clin Apheresis. 1993;  8 258-269
  PubMedGoogle Scholar
• 22 AABB Extracorporeal Therapy Committee .Guidelines for Therapeutic Hemapheresis: 1992-3. Bethesda, MD; American Association of Blood Banks 1992
  Google Scholar
• 23 Bandarenko N, Brecher M E. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.  J Clin Apheresis. 1998;  13 133-141
  CrossrefPubMedGoogle Scholar
• 24 Stegmayr B G. Plasmapheresis in severe sepsis or septic shock.  Blood Purif. 1996;  14 94-101
  PubMedGoogle Scholar
• 25 Stegmayr B G, Banga R, Berggren L, Norda R, Rydvall A, Vikerfors T. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure.  Crit Care Med. 2003;  31 1730-1736
  CrossrefPubMedGoogle Scholar
• 26 Valbonesi M, Giannini G, Carlier P et al.. TTP treated with the automatic cascade filtration module (DIDECO AutoCFM). WAA September 2002 (abst)
  Google Scholar
• 27 Gaddis T G, Guthrie T HJ, Drew M J, Sahud M, Howe R B, Mittelman A. Treatment of plasma refractory thrombotic thrombocytopenic purpuras with protein A immunoabsorption.  Am J Hematol. 1997;  55 55-58
  CrossrefPubMedGoogle Scholar
• 28 Snyder H W, Mittelman A, Oral A et al.. Treatment of cancer chemotherapy associated thrombotic thrombocytopenia purpura/hemolytic uremic syndrome by protein A immunoabsorption of plasma.  Cancer. 1993;  71 1882-1892
  PubMedGoogle Scholar
• 29 Bukowski R M, Hewlett J S, Reimer R R, Groppe C W, Weick J K, Livingston R B. Therapy of thrombotic thrombocytopenic purpura: an overview.  Semin Thromb Hemost. 1981;  7 1-14
  PubMedGoogle Scholar
• 30 Amir J, Krauss S. Treatment of thrombotic thrombocytopenic purpura with antiplatelet drugs.  Blood. 1973;  42 27-33
  CrossrefPubMedGoogle Scholar
• 31 Amorosi E L, Karpatkin S. Antiplatelet treatment of thrombotic thrombocytopenic purpura.  Ann Intern Med. 1977;  86 102-106
  PubMedGoogle Scholar
• 32 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS-13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
  CrossrefPubMedGoogle Scholar
• 33 Cataland S R, George I N, Kraut E H et al.. Improved clinical outcome and ADAMTS-13 activity following cyclosporine therapy in patients with TTP.  Blood. 2004;  104 243 , (abst)
  CrossrefPubMedGoogle Scholar
• 34 Zheng X L, Pallera A M, Goodnough I T et al.. Remission of chronic thrombotic thrombocytopenic purpura treated with cyclophosphamide and rituximab.  Ann Intern Med. 2003;  138 105-108
  CrossrefPubMedGoogle Scholar
• 35 Rock G, Kelton J G, Shumak K H, Buskard N A, Sutton D MC. and Members of the CAG . Laboratory abnormalities in thrombotic thrombocytopenic purpura.  Br J Haematol. 1998;  103 1031-1036
  CrossrefPubMedGoogle Scholar
• 36 Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.  Ann Oncol. 2003;  14 520-526
  CrossrefPubMedGoogle Scholar
• 37 Maloney D G, Grillo-Lopez A J, Bodkin D J et al.. IDEC-C2B8: results of phase I multiple dose trail in patients with relapsed non-Hodgkin's lymphoma.  J Clin Oncol. 1997;  10 3266-3274
  PubMedGoogle Scholar
• 38 Davis T A, White C A, Grillo-Lopez A J et al.. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of phase II trail of rituximab.  J Clin Oncol. 1999;  6 1851-1857
  PubMedGoogle Scholar
• 39 Ciiffier B, Lapage E, Briere J et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
  CrossrefPubMedGoogle Scholar
• 40 Hainsworth J D, Litchy S, Barton J H et al.. Single agent rituximab as first line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.  J Clin Oncol. 2003;  21 1746-1751
  CrossrefPubMedGoogle Scholar
• 41 van der Kolk L, Baars J, Prins M, van Oers M. Rituximab treatment results in impaired secondary humoral immune responses.  Blood. 2002;  100 2257-2259
  PubMedGoogle Scholar
• 42 Koulova L, Alexandrescu D, Dutcher J P, O'Boyle K P, Eapen S, Wiernik P H. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.  Am J Hematol. 2005;  78 49-54
  CrossrefPubMedGoogle Scholar
• 43 Chemnitz J, Draube A, Scheid C et al.. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.  Am J Hematol. 2002;  71 105-108
  CrossrefPubMedGoogle Scholar
• 44 Shumak K H, Rock G A, Nair R C. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group.  Ann Intern Med. 1995;  122 569-572
  CrossrefPubMedGoogle Scholar
• 45 Schneppenheim R, Budde U, Oyen F et al.. Von Willebrand factor cleaving protease and ADAMTS-13 mutations in childhood TTP.  Blood. 2003;  101 1845-1850
  CrossrefPubMedGoogle Scholar
• 46 Mannucci M, Canciani M T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of ADAMTS-13 that cleaves von Willebrand factor.  Blood. 2001;  98 2730-2735
  CrossrefPubMedGoogle Scholar
• 47 Moore J C, Haward C PM, Warentin T E, Kelton J G. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders.  Blood. 2001;  98 1842-1846
  CrossrefPubMedGoogle Scholar
• 48 Studt J D, Kremer Hovinga J A, Rodonic R et al.. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS-13 inhibitory autoantibodies in identical twins.  Blood. 2004;  103 4195-4197
  CrossrefPubMedGoogle Scholar
• 49 Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98 1765-1772
  CrossrefPubMedGoogle Scholar
• 50 Motto D, Zhang W, Zhu G et al.. Additional environmental and/or genetic factors are required to trigger TTP in ADAMTS-13-deficient mice.  Blood. 2004;  104 77 , (abst)
  PubMedGoogle Scholar
• 51 Gerritsen H E, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease.  Blood. 2001;  98 1654-1661
  CrossrefPubMedGoogle Scholar
• 52 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.  Blood. 2001;  98 1662-1666
  CrossrefPubMedGoogle Scholar
• 53 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic ursemic syndrome: the role of von Willebrand factor-cleaving protease.  Best Pract Res Clin Haematol. 2001;  14 437-454
  CrossrefPubMedGoogle Scholar
• 54 Studt J D, Kremer Hovinga J A, Alberio L, Bianchi V, Lämmle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.  Swiss Med Wkly. 2003;  133 325-332
  PubMedGoogle Scholar
• 55 Barbot J, Costa E, Guerra M et al.. Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease.  Br J Haematol. 2001;  113 649-651
  CrossrefPubMedGoogle Scholar
• 56 Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS-13).  Ann Hematol. 2002;  81 430-435
  CrossrefPubMedGoogle Scholar
• 57 Mori Y, Wada H, Gabazza E C et al.. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWF-cleaving protease activity.  Transfusion. 2002;  42 572-580
  CrossrefPubMedGoogle Scholar
• 58 Vesely S K, George J N, Lämmle B et al.. ADAMTS-13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
  CrossrefPubMedGoogle Scholar
• 59 Rock G, Shumak K, Kelton J, Blanchette V, Buskard N, Spasoff R. and the Members of the CASG . Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange.  Transfusion. 1992;  32 710-714
  CrossrefPubMedGoogle Scholar
• 60 George J N. ADAMTS-13 Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.  Curr Hematol Rep. 2005;  4 167-169
  PubMedGoogle Scholar

Gail RockM.D. Ph.D. F.R.C.P. 

Civic Campus, The Ottawa Hospital, 1053 Carling Avenue, Ottawa, Ontario K1Y 4E9, Canada

Email: grock@ottawahospital.on.ca